 SPARTA, N.J., Nov. 03, 2020 GLOBE NEWSWIRE -- PLx Pharma Inc. NASDAQ: PLXP PLx or the Company, a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuardTM delivery system to provide more effective and safer products, VAZALORETM 325 mg and VAZALORETM 81 mg referred to together as VAZALORETM, announced today that the Company will release its 2020 third quarter financial results on Friday, November 13, 2020, before the U.S. financial markets open. 